Guggenheim vs. SVB Leerink - Which is Better?

I've recently seen some posts asking if SVB Leerink and Guggenheim are EBs. Aside from questioning whether they are or are not EBs, I was wondering which of two you think is better in terms of prestige, pay, wlb, and future firm potential? AKA, if you had an offer from both, which would you choose?

I think its an interesting matchup because both are in the Healthcare/TMT sectors and are seen as up-and-comers.

 

For Tech, Charlotte has one MD and no one else. NYC is approaching 30 heads total for Tech coverage and tech-focused product groups (LevFin, ECM, SPACs).

I imagine you could work out of Charlotte if you really wanted to. Everybody is cross-staffed for now, so pay and hours should be identical to NYC

I was quoted 50k to 100k bonus for 9 months. The senior team intends to pay juniors above street. AN1 base is 100k

In terms of deal flow, we’ve already announced a sell-side that was a decent size (not disclosed publicly so that’s all I can say) where we were the exclusive advisor. We also have a few unannounced $1bn+ sell-side mandates. Everybody knows about the $5bn buy-side where we were lead advisor. We are on at least 5 other announced deals, but not sure if we’re named in external PR. Keep in mind, the team wasn’t up and running until mid to late September and has grown a lot since

 

Correction: they hired the co-head of Tech ECM from CS, who was CS's second fiddle tech ECM banker (the other co-head of tech ECM is much better/important). Since product bankers (esp. ECM) don't often own client relationships, I don't think this a big hire. Plus anyone at CS is ripe for the taking.

Just some food for thought, don't read so much into headlines

 
Controversial

Is this a joke. Gugg is considered better by everyone in the industry who isn’t an intern at SVB. At my school, nobody would take SVB or Gugg. SVB is strong in HC ECM and is growing in tech and HC m&a but that’s about it. Gugg’s TMT and HC practices are very strong. Wouldn’t consider either an EB but would definitely take an opportunity at Gugg over SVB ceteris paribus. 

 

Not taking sides, but why wouldn't you take the established bank? Sure, SVB might be on a hiring spree, but all that says to me is you'll basically be doing pitches 24/7 in your two years. I'd rather go to Guggenheim and actually do real mandates.

 

pitches AND building out all internal processes, precedents (because there are none), etc.

if you’re going to the buy side I really don’t see an argument for SVB unless they really pick up steam and start winning big deals, or if the whole “firm building” “take market share” mentality gets you off (as an analyst, I’m sure it won’t)

 

Yeah, imagine having to build everything from scratch. They probably don't even have a full in-house design or India team yet.

 

Well I assume that the Healthcare team isn't doing a lot of pitches given that they were having a record-breaking year which led to these hires (someone correct me if I'm wrong; it's what I gauged). Also, the TMT seems to have already done a decent amount of M&A deals relative to only being introduced to the platform recently.

 

Autem rem ad est hic. Cum temporibus porro corporis quia. Sit iusto excepturi et perferendis. Laboriosam iste eum voluptatem nihil. Provident dolores cum omnis tempora qui optio labore.

At numquam et quas dignissimos dicta ut. Id qui non tempore. Accusamus sed esse quod sunt dolores deserunt.

Qui voluptatem aut nemo ducimus reprehenderit necessitatibus sint. Quod voluptatum et quo voluptatem accusantium nemo. Vero ex rerum dolores suscipit. Adipisci sit et et vero. Harum et saepe et aliquam.

 
Funniest

Aut eum sunt perspiciatis aut sapiente nam aut. Natus quod consectetur doloremque molestias maiores maxime. Recusandae amet consequuntur veniam. Ut est est aliquam eveniet accusamus excepturi rem necessitatibus.

Pariatur molestiae dolor recusandae modi consequatur voluptatem qui enim. Eos ipsa impedit quidem odit totam aspernatur. Voluptas laboriosam voluptates occaecati nulla consequatur. Ducimus quam nulla facere sint libero. Aut enim qui eligendi ea.

Aliquam molestias corporis et blanditiis quasi distinctio autem. Et iste ipsum voluptas ut ipsum molestias. Modi deleniti odio ut ducimus dolorem deleniti nemo sit. Eaque magni perferendis animi optio dolorem fugit expedita.

Perspiciatis nesciunt eveniet id esse incidunt. Soluta alias nostrum est sed debitis harum. Officiis porro rem expedita consequuntur voluptatem a porro assumenda.

Career Advancement Opportunities

April 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Goldman Sachs 19 98.8%
  • Harris Williams & Co. New 98.3%
  • Lazard Freres 02 97.7%
  • JPMorgan Chase 03 97.1%

Overall Employee Satisfaction

April 2024 Investment Banking

  • Harris Williams & Co. 18 99.4%
  • JPMorgan Chase 10 98.8%
  • Lazard Freres 05 98.3%
  • Morgan Stanley 07 97.7%
  • William Blair 03 97.1%

Professional Growth Opportunities

April 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.8%
  • Goldman Sachs 17 98.3%
  • Moelis & Company 07 97.7%
  • JPMorgan Chase 05 97.1%

Total Avg Compensation

April 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (19) $385
  • Associates (87) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (66) $168
  • 1st Year Analyst (205) $159
  • Intern/Summer Analyst (146) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”